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ABSTRACT 
Objective: The aim of present work was to mask the bitter taste of sildenafil citrate by preparing drug resin complex (DRC) and develop sildenafil 
citrate 100 mg effervescent tablets.  
Methods: Sildenafil citrate and kyron T134 complexes were prepared at different conditions and evaluated for taste and drug loading. Optimized 
DRC was use to formulate the dispersible tablet by direct compression technique. A 32 full factorial design was use to study the effect of effervescent 
agent (X1) and croscarmellose sodium (X2) on dispersion time (Y1) and wetting time (Y2). Factorial batches were also evaluated for thickness, 
hardness, content uniformity, friability, in vitro drug release and stability studies. Multiple linear regression analysis, ANOVA and graphical 
representation of the influence factor by 3D plots were performing by using sigma plot 11.0. A Check point batch was design according to the results 
of desirability value and evaluated for all the parameter 
Results: 
Conclusion: Sildenafil citrate bitter tast was masked by kyron T134 and full factorial design result was indicate that independent variables have 
significant effect on dependent variables 
FT-IR study confirm that sildenafil citrate and kyron T134 were compatible with each other. Among the various DRC batch B29 was found 
with less bitter and give a more drug loading. Checkpoint batch showed no significance difference between predicted value and actual value for 
dispersion time and wetting time and it was found stable during stability study.  
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© 2020 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (
 full factorial design, kyron T134 
http://creativecommons.org/licenses/by/4.0/) 
DOI: http://dx.doi.org/10.22159/ijap.2020v12i4.37624. Journal homepage: https://innovareacademics.in/journals/index.php/ijap  
 
INTRODUCTION 
Oral route of drug administration is the most appealing route for the 
drug delivery but the numbers of orally administered drugs are 
bitter taste and that creates an unpleasant feeling in the mouth. 
Therefore, it is necessary to mask the bitterness for enhancing 
patient acceptability [1, 2]. Ion exchange resins are inexpensive and 
used to develop a simple, rapid and cost-effective method of taste 
masking. Ion exchange resins are cross-linked polymers containing 
salt forming groups in repeating positions on the polymer chain, 
have an affinity for oppositely charged counter ions, thus adsorbing 
the ions into the polymer matrix. For immediate release purpose, 
several ion-exchange resins have been developed for oral 
administration. Kyron T134 is a derivative of cross-linked 
polyacrylic polymer used to mask the bitter of medicines. It is also a 
weak acid derivative of acrylic acid cross-linked polymer having 
carboxylic acid functional group, which contains K+ionic form [3, 4].  
Sildenafil citrate, a selective inhibitor of phosphodiesterase type 5 
enzymes (PDE5) and it is use for the treatment of erectile 
dysfunction. It has extreme bitter taste resulting in poor patient 
compliance. Conventional sildenafil citrate tablets available in 
market are not sutable when quick onset of action is required. It 
needs to be taken before at least 30 min for the desired action due 
to slow release of the drug. Thus, effervescent tablet can 
potentially achived rapid onset of desirable action in a convenient 
manner [5, 6].  
The present work was carried out to develop sildenafil citrate 100 
mg effervescent tablets, which will mask the bitter test of drug with 
ion-exchange resin and make the immediate release formulation for 
quick onset of action.  
MATERIAL AND METHODS 
Materials 
Sildenafil citrate was received as a generous gift from Phanicare 
chemicals, Hyderabad, India. Kyron T134 was obtaining from Corel 
pharma chem., Ahmedabad, India. Croscarmellose sodium was 
purchase from Madhu hydrocolloids Pvt. Ltd., Ahmedabad. All other 
materials and chemicals used were of either pharmaceutical or 
analytical grade.  
Drug-excipients compatibility study 
Drug-excipients interaction plays a vital role in achieving stability of 
drug in dosage form. Fourier transform infrared spectroscopy (FT-
IR) was used to study the physical and chemical interactions 
between drug and excipients. DSC and FT-IR spectra of sildenafil 
citrate, kyron T134 and DRC were obtain by using FT-IR instrument. 
(FT-IR-1700, Shimadzu, Kyoto, Japan). Thermograms of sildenafil 
citrate and drug-excipients physical mixture were obtain by using an 
automatic thermal analyzer system (DSC 60, Shimadzu, Japan). The 
analysis was performed at a rate of 20 °C/min from 50 °C to 300 °C 
under a nitrogen flow of 25 ml/min [7, 8]. 
Development and evaluation of drug resin complex (DRC)  
In batch process drug resin complex was develop using different 
process variables. In this process, activated resin was placed in a 
beaker that containing deionized water. Different ratio of sildenafil 
citrate and kyron T134 was add and stirred for different periods at 
various pH as shown in table 3. Batch B1 to B4 was contained 
sildenafil citrate with different ratio of kyron T134 and stirred for 
240 min. Then, the mixture was filter and residue was wash with 
deionized water. For an optimization DRC was prepared at different 
pH, temperature, soaking time of resin and stirring time. Batch B5 to 
B12 was developed at various pH. Batch B13 to B17 was prepared at 
40 °C, 50 °C, 60 °C, 70 °C and 80 °C. Batch B18 to B25 was prepared 
to check the effect of soaking time on drug loading. Using previously 
optimized conditions batch B26 to B32 was prepared to check the 
effect of stirring time on drug loading [9, 10]. All batches were 
evaluated for taste and % of drug loading. 
Prepared DRC taste evaluation was done by a panel of 6 volunteers 
in the age group of 20 to 25 y using time intensity method. Each 
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volunteer held equivalent to 100 mg sildenafil citrate in the mouth 
and bitterness were record up to 1 min against pure drug. The yield 
of DRC was calculated using following equation. 
%yield =
Weight of complex obtained 
Theoritical weight of complex
× 100 
In vitro drug release of optimized batch DRC was determined using a 
USP XXIV type II dissolution apparatus. Drug equivalent to 100 mg 
DRC was add in 900 ml 0.01 M HCl and maintained at 37 °C. Sample 
was withdrawn at definite time interval and the amount of drug was 
estimated spectrophotometrically at 292.5. Drug release from the 
DRC was also perform in deionized water by repeating same 
procedure [11, 12]. 
Preliminary trail of sildenafil citrate 100 mg effervescent tablets  
Direct compression technique was use to develop sildenafil citrate 100 
mg effervescent tablets. Preliminary trail of effervescent tablets were 
prepared as described in table 1. Preliminary trail batch was prepared 
to check the effect of effervescent agent and croscarmellose sodium on 
dispersion time and wetting time. As an effervescent agent Citric acid: 
Tartaric acid: Sodium bicarbonate (1: 2: 3.44) was taken. All the raw 
materials were passed through sieve no. 40 and it was mixed in a 
geometrical order for 15 min. Aerosil, Talc and magnesium stearate 
were add before compression. Compression was Carry out using flat 
round shape punch. At the time of manufacturing of effervescent 
tablets, humidity and temperature was maintained at 25 % RH and 25 ˚ 
C respectively [13, 14]. 
 
Table 1: Preliminary trail of sildenafil citrate 100 mg effervescent tablets 
Ingredients Quantity in mg 
T1 T2 T3 T4 T5 T6 T7 
DRC* 426 426 426 426 426 426 426 
effervescent agent # 0 483 580.5 675 750 750 750 
Croscarmellose sodium 45 45 45 45 45 30 0 
Betacyclodextrin 45 45 45 45 45 45 45 
Lactose: Mannitol (50: 50) 898.5 384 286.5 192 132 147 177 
Sucralose 30 30 30 30 30 30 30 
Dry orange flavor 30 30 30 30 30 30 30 
Sunset yellow Color 1.5 1.5 1.5 1.5 1.5 1.5 1.5 
Aerosil 7.5 15 15 15 15 15 15 
Talc 7.5 22.5 22.5 22.5 22.5 22.5 22.5 
Magnesium stearate 7.5 18 18 18 18 18 18 
Total 1500 1500 1500 1500 1500 1500 1500 
*Drug resin complex (DRC) contain Sildenafil citrate 100 mg and kyron T134, #effervescent agent = Citric acid: Tartaric acid: Sodium bicarbonate 
(1: 2: 3.44) 
 
Evaluation of sildenafil citrate 100 mg effervescent tablets 
Bulk density, Tapped density, Carr's index, Angle of repose, Average 
weight, Thickness, Hardness, Weight variation and % Friability of 
the effervescent tablets were measured as described by Yadav K et 
al., Khar RK et al, Madgulkar AR et al., and Lakade SH et al., 
respectively [15-18]. 
Dispersion time: Dispersion time was measured by dropping a tablet 
in a measuring cylinder containing 6 ml of deionized water. The time 
for the tablet to completely disintegrate into fine particles was 
noted. Six tablets from each batch were randomly selected and 
dispersion time was recorded. 
Wetting time: It was measure by using five circular tissue papers of 
10 cm in diameter, which was place in a petridish of 10 cm diameter. 
10 ml of eosin solution was adding to the petridish. A tablet was 
carefully place on the surface of the tissue paper. The time for 
complete wetting was noted and recorded as the wetting time.  
In vitro drug release of effervescent tablets was determined using by 
USP XXIV type II dissolution apparatus at 100 rpm. A tablet was add 
to 900 ml 0.01 M HCl for 30 min at 37±0.5 °C. At predetermined time 
intervals, 10 ml of the sample was collect and replaced with the 
same volume of fresh medium. Solution was dilute and assay at 
292.5 nm using a UV-Vis double beam spectrophotometer.  
Taste analysis: All the batches of tablets were subject to gustatory 
sensory evaluation test performed by a panel of ten volunteers. The 
volunteers selected randomly and instructed to rate the samples as 
per the taste evaluation scale [19-20]. 




2full factorial design was use in the present study. Formulation of 
factorial batches was show in table 2. On the basis of preliminary 
results, the amount of effervescent agent (X1) and amount of 
croscarmellose sodium (X2) were chosen as independent variables 
in 32 full factorial design, while dispersion time (DT) and wetting 
time (WT) were taken as dependent variables. Multiple linear 
regression analysis, ANOVA and graphical representation of the 
influence of factor by contour plots were perform using sigmaplot 
11.0. The experimental runs and measured responses of 32
 
 full 
factorial design batches of sildenafil citrate 100 mg dispersible 
tablets were deplete in table 7 [21-23]. 
Table 2: Factorial batches of sildenafil citrate 100 mg effervescent tablets 
Ingredients Quantity in mg 
F F1 F2 F3 F4 F5 F6 F7 F8 9 
DRC* 426 426 426 426 426 426 426 426 426 
Effervescent agent 450 450 450 600 600 600 750 750 750 
Croscarmellose sodium 30 45 60 30 45 60 30 45 60 
Lactose: Mannitol (50: 50) 477 462 447 327 312 297 177 162 147 
Sucralose 30 30 30 30 30 30 30 30 30 
Dry orange flavor 30 30 30 30 30 30 30 30 30 
Sunset yellow Color 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 1.5 
Aerosil 15 15 15 15 15 15 15 15 15 
Talc 22.5 22.5 22.5 22.5 22.5 22.5 22.5 22.5 22.5 
Magnesium stearate 18 18 18 18 18 18 18 18 18 
Total 1500 1500 1500 1500 1500 1500 1500 1500 1500 
*Drug resin complex (DRC) contain Sildenafil citrate 100 mg and kyron T134, #effervescent agent = Citric acid: Tartaric acid: Sodium bicarbonate 
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(1: 2: 3.44) 
Stability study of sildenafil citrate effervescent tablets 
Optimized batch was packed in aluminum foil and was placed for 
stability study at 40˚C/75% RH for 3 mo. Sample was evaluated after 
3 mo for physical parameters and In vitro dissolution. The 
dissolution profile of product was compare using similarity factor, f2, 













where log is logarithm to the base 10, n is the number of time points, 
∑ is summation over all time points, Rt is the mean dissolution value 
of the reference profile at time t and Tt is the mean dissolution value 
of the test profile at the same time point. The USFDA draft guidance 
document contains more information on similarity factor (f2). The 
value of similarity factor (f2) between 50 and 100 suggests that the 
two dissolution profiles are similar [24-26]. 
RESULTS AND DISCUSSION 
The powder characteristics of sildenafil citrate like angle of repose, 
Hausner’s ratio and Carr’s index showed that drug is poorly 
compressible and have poor flow properties. So in present study, 
directly compressible excipient were selected which improved flow 
property, compressibility and also gives desired drug release. 
Drug excipients compatibility study 
IR spectra of sildenafil citrate, kyron T134 and DRC are show in fig, 
1. The IR spectrum of DRC was found to exhibit some significant 
difference in the characteristic peaks of sildenafil citrate, revealing 
modification of the drug environment. As shown in the fig. 1 (A), a 
peak was observed at 3299 cm-1. IR spectra of DRC showed in fig. 1 
(C) shifting of peak this peak from 3299 to 3309 cm-1
 
. Shifting of this 
peak suggests the formation of new N-H stretching which was 
previously absent in pure drug. This shows the formation of complex 
of drug with resin. Thermogram of DSC of sildenafil citrate, kyron 
T134 and DRC are show in fig. 2. Thermogram of sildenafil citrate 
showed endothermic peak at 188.64˚C whereas DRC showed 
endothermic peak at 188.20˚C. Therefore, there was negligible 
change in the melting peak of sildenafil citrate. Therefore, it was 
confirm that sildenafil citrate and kyron T134 were compatible with 
each other [27, 28]. 
 
Fig. 1(A): Infrared spectra of sildenafil citrate 
 
 
Fig. 1(B): Infrared spectra of kyron T134 
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Fig. 1(C): Infrared spectra of DRC 
 
Optimization of drug resin complex (DRC) using different 
process variables  
Drug resin complex was developed by using different process 
variables. Batch B1 to Batch B4 was prepare by varying the ratio of 
sildenafil citrate to kyron T134 and drug loading efficiency and 
bitterness level was observe. From the results, it was clearly reveal 
that drug loading increases with increase in drug resin ratio. There 
was no significant difference in drug loading as well as taste, when 
drug: resin ratio was change from 1:2 to 1:3 and 1:4. Therefore, the 
drug-resin ratio of 1:2 was use to check the effect of pH on drug 
loading. pH was shown significant change on drug loading efficiency. 
There was no change in drug loading when pH was changed from 7 
to 9. So, the deionized water used as a medium for further 
optimization. Here, the effect of temperature on drug loading was 
measured using drug: resin ratio 1:2 and pH 7. Results showed that 
there was no significant change in drug loading efficiency on change 
in temperature. So 30 °C was select for futher study. Batch B19 to 
B25 was show drug loading was increases with soaking time up to 
30 min. There was no significant difference was observe, when 
soaking time was change from 30 min to 120 min. Thus, the 30 min 
soaking time was used as optimized time for obtain maximum drug 
loading. Batch B26 to B32 was prepared to check the effect of 
stirring time. The result was show that above 240 min drug loading 
was not increase. Therefore, batch B29 was use for the further 
studies to prepare sildenafil citrate dispersible tablet. 
 
 
Fig. 2(A): DSC spectrum of sildenafil citrate 
 
 
Fig. 2(B): DSC spectrum of kyron T134 
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Fig. 2C: DSC spectrum of of DRC 
 
Table 3: Development and evaluation of drug resin complex (DRC) 
Batch Drug: resin ratio Soaking time (min) pH Stirring time (min) Temp Taste % Drug loading 
B1 1:1 30 7 240 30 °C + 74.40±1.09 
B2 1:2 30 7 240 30 °C 0 95.59±0.54 
B3 1:3 30 7 240 30 °C 0 96.07±0.54 
B4 1:4 30 7 240 30 °C 0 97.85±0.54 
B5 1:2 30 2 240 30 °C + 71.14±0.74 
B6 1:2 30 3 240 30 °C + 75.23±0.54 
B7 1:2 30 4 240 30 °C + 84.99±0.94 
B8 1:2 30 5 240 30 °C + 90.23±0.54 
B9 1:2 30 6 240 30 °C + 93.92±0.71 
B10 1:2 30 7 240 30 °C + 95.59±0.54 
B11 1:2  30 8  240 30 °C + 96.06±0.71 
B12 1:2 30 9 240 30 °C + 96.30±0.90 
B13 1:2 30 7 240 40 °C + 95.59±0.54 
B14 1:2 30 7 240 50 °C + 94.75±0.54 
B15 1:2 30 7 240 60 °C + 94.52±0.54 
B16 1:2 30 7 240 70 °C + 93.92±0.71 
B17 1:2 30 7 240 80 °C + 94.16±0.54 
B18 1:2  00 7 240 30 °C + 94.63±0.61 
B19 1:2 10 7 240 30 °C + 78.63±0.69 
B20 1:2 20 7 240 30 °C + 88.80±0.90 
B21 1:2 30 7 240 30 °C + 95.59±0.54 
B22 1:2 45 7 240 30 °C + 95.71±1.07 
B23 1:2 60 7 240 30 °C + 95.94±0.54 
B24 1:2 90 7 240 30 °C + 96.18±0.54 
B25 1:2 120 7 240 30 °C + 95.95±1.09 
B26 1:2 30 7 060 30 °C + 58.56±0.71 
B27 1:2 30 7 120 30 °C + 69.52±0.54 
B28 1:2 30 7 180 30 °C + 85.47±0.74 
B29 1:2 30 7 240 30 °C + 95.59±0.54 
B30 1:2 30 7 300 30 °C + 96.06±0.94 
B31 1:2 30 7 360 30 °C + 96.18±0.54 
B32 1:2 30  7 420 30 °C + 96.30±1.450 
++++= Very bitter,+++= Bitter,++= Less bitter,+= Very less bitter 
 (n=6) 
 
In vitro drug release from DRC 
In this study, sildenafil citrate release from drug resin complex was 
observe in 0.01 M HCl and deionized water separately. In 0.01 M HCl, 
more than 90% of drug was release within 2 min, whereas in 
deionized water, less than 15% drug was release within 20 min. In 
vitro drug release from DRC in deionized water was negligible 
indicating potential application in effervescent tablets. In addition, 
drug release of almost 100% within 4 min in 0.01 M HCl is favorable 
for effervescent tablets. 
 
Table 4: Preliminary trail batch evaluation of sildenafil citrate 100 mg effervescent tablets 
Batch Dispersion time(s) Wetting time(s) 
T1 160.66±2.51 43.13±1.15 
T2 97.33±1.52 28.66±0.57 
T3 89.66±2.08 24.33±0.57 
T4 85.33±1.52 21.66±1.15 
T5 78.33±1.15 18.33±0.57 
T6 74.33±0.57 15.33±0.57 
T7 113.33±1.52 34.66±0.57 
(n=6) 
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Preliminary trail batch evaluation of sildenafil citrate 100 mg 
dispersible tablets 
In vitro dispersion time and wetting time of preliminary batches 
were determined to check the effect of effervescence agents and 
crosscarmellose sodium. From results shown in table 4, it was clear 
that amount of effervescence agents and croscarmellose sodium 
showed significant effects on dispersion time and wetting time of the 
effervescent tablets. An increase in the amount of effervescence 
agents and croscarmellose sodium showed significant decrease in 
dispersion time and wetting time of the tablets. Hence, amount of 
effervescence agents and crosscarmellose sodium were select as 
optimize factors for sildenafil citrate 100 mg effervescent tablets. In 
batch T1, only super disintegrant was use to formulate the tablets 
without using effervescence agents that showed very high 
dispersion time and wetting time. This clearly indicates that 
effervescence agents had the significant effects on both dispersion 
time and wetting time. Therefore, an effervescence agent was taking 
as one of the factor for the effervescent tablets. Batch T7 was 
formulated by using only effervescence agents without super-
disintegrant. The results showed increased in vitro dispersion time 
and wetting time. This suggests that super-disintegrant significantly 
affects the in vitro dispersion time and wetting time. Therefore, 
super-disintegrant was select as another factor for the effervescent 
tablets. In a preliminary trial, batchs β-cyclodextrin was use to 
improve the solubility of the drug. However, the drugresin complex 
did not allow the drug to release in deionize water. The sildenafil 
citrate and kyron T134 complex was already showed significant 
drug release in gastric pH. Therefore, β-cyclodextrin was not use in 
the formulation of factorial batches. 
32
A statistical model incorporating interactive and polynomial terms 
was use to evaluate the responses:  
 full factorial design model evaluation 
Y=b0+b1X1+b2X2+b11X12+b22X22
where, Y is the dependent variable, bo is the arithmetic mean 
response of the 9 runs and any bi is the estimated coefficients for the 
related factor Xi. The main effects (X1 and X2) represent the average 
result of changing one factor at a time from its low to high value. The 
polynomial terms (X12 and X22) are included to investigate 
nonlinearity. The interaction term “X1X2” shows how the response 
changes when the two factors change simultaneously. Evaluation 
data of pre-compression and post-compression parameters of 
factorial batches and in vitro % drug release were presented in table 
5 and table 6. Table 7 describes the effect of independent variables 




 full factorial designs. The fitted 
equations (full model) relating the responses that are dispersion 
time and wetting time to the transformed factor were shown in table 
8 and table 9. The polynomial equation can used to draw conclusion 
after considering the magnitude of coefficient and the mathematical 
sign it carries (i.e. positive or negative). The results of ANOVA 
suggested that calculated F values for dispersion time and wetting 
time are 31.38 and 101.57, respectively (table 8). Tabulated F value 
was found to be 9.013 at α = 0.05. Calculated F values are greater 
than tabulated for all dependent variables therefore factors selected 
have shown significant effects. From the results of multiple 
regression analysis, it was found that both factors had statistically 
significant influence on all dependent variables as p<0.05 [29, 30]. 























F1 0.71±0.02 0.83±0.01 14.25±1.18 28.61˚±0.23 1504.25±4.66 2.69±0.02 3.32±0.27 0.73±0.04 101.69±0.75 
F2 0.68±0.05 0.80±0.02 11.04±1.18 29.05˚±0.75 1503.25±3.72 2.72±0.02 3.44±0.22 0.73±0.02 101.81±1.30 
F3 0.74±0.07 0.86±0.03 14.81±1.18 28.17˚±0.57 1504.0±4.75 2.70±0.01 3.51±0.35 0.76±0.05 103.39±1.10 
F4 0.76±0.06 0.86±0.01 11.53±1.18 29.51˚ 0.46 1504.0±4.72 2.71±0.01 3.41±0.41 0.85±0.07 101.81±0.72 
F5 0.66±0.02 0.76±0.05 13.33±1.18 27.34˚±0.54 1505.0±4.58 2.73±0.02 3.45±0.22 0.72±0.09 101.93±1.79 
F6 0.76±0.03 0.86±0.06 11.53±1.18 27.75˚±0.23 1504.25±4.44 2.70±0.01 3.75±0.44 0.82±0.03 102.90±1.09 
F7 0.66±0.02 0.74±0.02 10.0±1.18 27.34˚±0.86 1505.0±4.28 2.71±0.03 3.27±0.2 0.69±0.01 102.78±1.16 
F8 0.71±0.06 0.83±0.01 14.25±1.18 26.95˚±0.67 1503.75±3.59 2.73±0.03 3.35±0.44 0.66±0.04 103.75±0.91 
F9 0.68±0.05 0.76±0.04 10.34±1.18 26.56˚±0.45 1503.5±4.61 2.68±0.03 3.47±0.22 0.59±0.05 101.81±0.36 
 (n=6) 
 
Table 6: In vitro dissolution of factorial batches of sildenafil citrate 100 dispersible tablets 
Time 
(min) 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
0 0 0 0 0 0 0 0 0 0 
2 82.4±0.59 84.1±0.78 86.3±0.98 87.3±0.81 83.8±1.19 88.6±1.25 84.3±0.45 89.3±1.19 90.5±0.98 
4 95.2±1.37 95.7±1.19 96.7±0.81 97.5±0.59 97.1±0.59 97.4±0.67 97.8±0.67 97.9±0.45 98.0±0.22 
6 97.6±0.81 98.4±0.60 97.8±1.03 97.8±0.39 98.0±0.81 98.7±0.45 98.2±1.03 98.7±0.45 99.1±0.22 
8 98.9±0.39 98.6±0.39 98.4±0.90 98.8±0.98 99.1±0.22 99.3±0.39 99.3±0.39 99.1±0.22 99.6±0.19 
10 99.2±0.22 98.9±0.39 99.0±0.36 99.2±0.45 99.6±0.22 99.5±0.59 99.6±0.59 99.3±0.32 99.6±0.07 
15 99.3±0.39 99.2±0.22 99.6±0.22 100.0±0.22 99.7±0.78 100.1±0.39 100.0±0.90 99.7±0.39 100.1±0.67 
20 99.6±0.22 99.7±0.39 99.6±0.59 100.4±0.22 100.1±0.39 100.6±0.81 100.6±0.45 100.2±0.45 100.4±0.59 
 (n=6) 
 
Full and reduced model for dispersion time 
DT = 75.910–(4.900 X1)–(6.900 
X2)+(0.033X1X2)+(2.833X12)+(0.750X22
When effervescent agent and croscarmellose sodium was increase 
dispersion time decrease. From the 3D plot (fig. 3A) and the 
regression coefficient values of factors, it was concluded that 
croscarmellose sodium give more significant than effervescent 
agent. Both the effervescent agent and croscarmellose sodium 
showed significant effect in the model. Interaction and nonlinearity 
was not observed. For dispersion time, the significance levels of the 
coefficients b11, b22 and b12 were found to be 0.979, 0.098 and 0.440 
respectively, so they were omitted from the full model to generate a 
reduced model. The coefficients b0, b1 and b2 significant at P<0.05; 
hence they were retained in the reduced model. The reduced model 
for drug dispersion time,  
) 
DT = 75.910–(4.900 X1)–(6.900 X2) 
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Table 7: Runs and measured responses of 32
Batch 




Amount of croscarmellose 
sodium (X2) 
Dispersion time (Sec) 
(Y1) 
Wetting time (Sec) 
(Y2) 
F1 -1 -1 92.6±3.07  23.0±0.45 
F2 0 -1 84.4±1.35 22.33±0.57 
F3 1 -1 80.0±1.41 20.66±0.87 
F4 -1 0 79.2±1.16 16.66±0.87 
F5 0 0 76.6±1.62 15.33±0.59 
F6 1 0 72.0±1.41 14.66±0.32 
F7 -1 1 76.4±2.05 14.33±0.25 
F8 0 1 72.4±1.01 11.66±0.78 
F9 1 1 66.8±1.60 10.66±0.85 
Factors and the levels in the design 
Independent variables Low (-1) Medium (0) High (1) 
Amount of effervescent agent (X1) 450 600 750 
Amount of Croscarmellose sodium (X2) 30 45 60 
(n=6) 
 
Table 8: Results of the ANOVA for dependent variables 
Source of variation DF SS MS F value P value 
Dispersion time 
Regression 5 448.030 089.610 31.380 0.009 
Residual 3 008.570 002.860 
Total 8 456.600 057.074 
wetting time 
Regression 5 159.550 031.910 101.570 0.002 
Residual 3 000.940 000.310 
Total 8 160.500 031.910 
 
Table 9: Summary of regression output of factors for measured responses 
Responses Model Coefficient of regression parameters 
b0 b1 b2 b11 b22 b12 R2 
Dispersion time Full 75.910 –4.900 -6.900 +0.033 2.833 0.750 0.981 
Reduced 75.910 –4.900 -6.900 - - - 
wetting time Full 15.402 -1.335 -4.890 0.222 1.557 0.333  0.994 
Reduced 15.402 -1.335 -4.890 - 1.557 - 
 
Full and reduced model for wetting time 
WT = 15.402-(1.335X1)-(4.890 X2)+(0.222 X1 X2)+(1.557 X12)-(0.333 
X22
From the 3D plot (fig. 3B) and the regression coefficient values of 
factors, it was concluded that when effervescent agent and 
croscarmellose sodium was increase that time wetting time 
decrease. The results also indicated that the croscarmellose 
sodium was given a more significant on wetting time. Both the 
effervescent agent and croscarmellose sodium showed significant 
effect in the model. Interaction and nonlinearity was not observed. 
For wetting time the significance levels of the coefficients b11 and 
b12 were found to be P= 0.615 and 0.321 respectively, so they were 
omitted from the full model to generate a reduced model. The 
coefficients b1, b2 and b12 was found to be significant at P<0.05; 
hence, it was retained in the reduced model [31]. The reduced 
model for wetting time,  
) 




Fig. 3A: 3D plot showing the effect of effervescent agent and Croscarmellose sodium on dispersion time 
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Fig. 3B: 3D plot showing the effect of effervescent agent and Croscarmellose sodium on wetting time 
 
 
Fig. 3C: Desirability plot 
 
Formulation and evaluation of check point batch 
A checkpoint batch was designed accordance to the desirability 
function as shown in fig. 3C. To validate the evolved mathematical, a 
checkpoint batch was prepared and evaluated under the same 
conditions as outlined for the other batches. The response data was 
compared with predicted data. The application of desirability 
function gives possibility to predict the optimum levels for the 
independent variables. In this study, the following constraints were 
used for the selection of an optimized batch: Dispersion time was 70 
to 72 s and wetting time was 10 to 12 s. Desirability plot showed 
that prediction is 1 when 743.44 mg of effervescence agents and 
47.25 mg of Croscarmellose sodium are used. So, checkpoint batch 
was formulated and validated by using same amount of effervescent 
agents and Croscarmellose sodium. Results of validation of check 
point batch are shown in table 10. Results of in vitro dispersion time 
and wetting time showed no significance difference between 
predicted value and actual value, which suggests that the evolved 
models may be used for theoretical prediction of responses within 
the factor space. After short-term stress stability studies check point 
batch initial in vitro release profile was compared using similarity 
factor, (f2) value which was found to be 89.50±1.52%. There is no 
significant difference in similarity factor. Other stability evaluation 
parameter after 3 mo was shown in table 11. No significant changes 
were observed in any parameters during the study period, thus it 
could be concluded that formulation was stable. 
 
Table 10: Formulation of checkpoint batch and comparison with predicted value 
Independent variable Dispersion time (sec) Wetting time (sec) 
Predicted value Actual value Predicted value Actual value 
X1 (Effervescence agents) =743.44 mg 71.27 73±0.45 11.90 12±46 
X2 (Croscarmellose sodium)= 47.25 mg 
(n=6) 
 
Table 11: Evaluation of checkpoint batch after stability study 
S. No. Parameters Initial After 3 mo 
1 Appearance Light orange colour, No change 
2 Hardness (Kg/cm2 3.3±0.44 ) 3.4±0.22 
3 Friability 0.666 % 0.676 % 
4 Dispersion time (Sec) 72.4±1.01 72.8±1.30 
5 Wetting time (Sec) 11.66±0.57 12.0±1.0 
(n=6) 
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CONCLUSION 
The objective of the present investigation was to formulate, evaluate 
and optimize the of sildenafil citrate 100 mg dispersible tablets to 
achieve quick disintegration and fast release of the drug. Kyron 
T134 was used as taste masking agent that showed highest % of 
drug loading and test masking. These formulations were evaluated 
for the parameters like drug excipient compatibility study, thickness, 
hardness, weight variation, % friability, disintegration test, in vitro 
drug release and accelerated stability studies. Based on preliminary 
results, the amount of effervescence agents (X1) and the amount of 
Crosscarmellose sodium (X2) were chosen as independent variables 
in 32
FUNDING 
 full factorial design, while dispersion time and wetting time of 
the tablets were taken as dependent variables. Multiple linear 
regression analysis, ANOVA and graphical representation of the 
influence of factor by 3D plots were performed using Sigma plot 
11.0. From the results of multiple regression analysis, it was found 
that both factors had significant influence on all dependent 
variables. A Check point batch was design according to the results of 
desirability value and evaluated for all the parameter. The results of 
comparison of predicted response and obtained response were 
found in good agreement. The formulation was found to be stable 
during accelerated stability study.  
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